Plasma Levels of Danger-Associated Molecular Patterns in Young Children After Cardiac Surgery Under Cardiopulmonary Bypass — IMMUNOPED2  

Cardiac Surgical Procedure Clinical Trial

Official title: Plasma Levels of Danger-Associated Molecular Patterns (DAMPs) in Young Children After Cardiac Surgery Under Cardiopulmonary Bypass (IMMUNOPED 2)

Status Recruiting

Clinical Trial Summary

The investigators have previously reported that cardiac surgery with CPB ( cardiopulmonary bypass) in young infants induced a drastic reduction in mHLA-DR ( Human Leucocyte Antigen) expression, which represents one of innate immune mediator. Danger-Associated Molecular Patterns (DAMPs) can elicit immune response and may subsequentely induce an immune-suppressed state. The investigators hypothesize that CPB causes excessive DAMP release, leading to the development of immune suppression. Thus, DAMPs release will be assessed in patients undergoing CBP, and consequences on immune suppression will be evaluated.

Clinical Trial Description

Plasma levels of heat shock protein (HSP 70), high mobility group box (HMGB1), S100A9 and IL-33 will be measured at four time points (prior to the onset of CPB, Hour 6 postoperative, day 1 and day 3 after surgery). HLA-DR gene expression will be determined before surgery and at day 3 postoperative. The direct effect of DAMPs release and immune suppression will be assessed by in vitro experiments. ;

Related Conditions & MeSH terms

• Cardiac Surgical Procedure

• NCT number: NCT04423523
• Study type: Observational [Patient Registry]
• Source: Nantes University Hospital
• Contact: Alexis Chenouard, ph
• Phone: 02.44.76.82.21
• Email: alexis.chenouard@chu-nantes.fr
• Status: Recruiting
• Start date: September 2, 2020
• Completion date: April 2, 2025